Rene Haas, CEO of UK-based semiconductor leader Arm Holdings, envisions artificial intelligence dramatically reshaping healthcare in the foreseeable future, possibly even leading to a cure for cancer. While Arm’s valuation soars to new records, Haas cautions that the swift evolution of AI could be hindered by supply chain obstacles within the sector itself.
Medicine on the Brink of Digital Transformation
At the helm of Arm Holdings in Cambridge—a chip design powerhouse behind so many of the world’s devices—Haas points out that understanding all genetic markers involved in cancer currently remains beyond the reach of humans. However, he believes rapidly advancing computational power will eventually allow AI to bridge this complexity. Speaking recently on the Big Boss Interview podcast, Haas stated, “AI is going to… find a cure for cancer that today you and I, other humans [could] not in our lifetimes,” sharing his belief that, “In our lifetime, AI will help cure cancer.”
Although existing AI models and computers cannot yet fully model a human or even a single cell, Haas thinks that as AI systems become increasingly advanced and varied, technology will be able to tackle today’s most intricate medical questions. In addition to leading Arm, Haas also holds an executive seat at SoftBank, the Japanese group that owns most of Arm and has major investments in areas like OpenAI.
According to Professor Chris Bakal, CEO of Sentinal4D and researcher at the Institute of Cancer Research in London, the pace of AI progress in medicine will rely chiefly on the quality of the data used for training, not merely hardware size. “The real question was no longer whether we use AI, it’s what we feed it,” Bakal commented, describing how his team inputs data from patient samples into AI. He anticipates breakthroughs will be realized when AI is matched with precise, relevant measurements—reducing the time needed for new treatments and speeding up patient benefits.
Robots, the Workforce, and the AI Supply Challenge
Haas predicts that AI will soon supercharge the use of human-like robots in manufacturing, security, and services, with substantial progress expected within five years. Future robots may quickly learn new functions, from hotel housekeeping to technical repairs, thanks to Arm-designed self-learning chips.
Even with debates about automation threatening jobs, Haas contends that while the nature of work will inevitably evolve, “the estimates of jobs going away and being completely replaced by machines is a bit overstated.” He argues that opportunities created by AI will surpass any job destruction, as workers shift into fresh roles.
Haas further addressed speculation about a bubble in the AI sector, crediting persistent, robust demand for artificial intelligence with maintaining market stability. Today, around half of all AI data centres globally rely on Arm’s power-efficient chip technology, he said.
Meta (Facebook’s parent company) has recently tapped Arm to produce the Arm AGI chip, which saw over $2 billion in demand since its introduction in March. However, despite such demand, growth in AI and data centre construction is hampered by current chip shortages. “We are absolutely in a supply-constrained environment,” Haas explained, alluding to major data centre initiatives in France, the US, and outer space, and underscoring the immediate need for additional chip factories (“fabs”).
Manufacturing Outlook and Arm’s Strong Ties to the UK
Despite the British government’s interest in building domestic chip factories, Haas expressed skepticism about the feasibility of manufacturing chips in the UK. He pointed to the significant expenses, specialized staffing demands, and intense resource requirements, arguing that the global supply chain—largely controlled by TSMC in Taiwan—makes local manufacturing difficult to justify for Britain.
Discussing the company’s partial 2016 sale to Japanese investors and subsequent listing on Nasdaq, Haas reaffirmed Arm’s ongoing dedication to its UK roots. Half of Arm’s workforce remains based in the UK, and it still holds the title of Cambridge’s largest private employer.
As the world moves through both the promise and the complexities of the AI surge—from advancing health treatments to powering unprecedented chip demand—Arm Holdings stands central, steering through a landscape shaped by worldwide markets, intricate supply dynamics, and breakthroughs in science.